Phase I Safety and Pharmacokinetics Study of Micronized Atovaquone in Human Immunodeficiency Virus-Infected Infants and Children
A phase I dose-escalating safety and pharmacokinetic study evaluated an oral suspension of micronized atovaquone (m-atovaquone) in infants and children stratified into age groups from 1 month to 12 years of age. Dosages of 10, 30, and 45 mg/kg of body weight/day were evaluated as single daily doses...
Na minha lista:
| Udgivet i: | Antimicrob Agents Chemother |
|---|---|
| Principais autores: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Microbiology (ASM)
1998
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC105594/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9624466/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.42.6.1315 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
